CVR Medical Corp (CRRVF)

[n3m3sis]

Older News but important!

CVR Medical Enters China, Executes Preliminary LOI To Launch Its CSS Device In World’s Largest Market
Hamza Ghaznavi - January 17th, 2018
Potential To Bring Innovation, Sweeping Change To Healthcare In China






CVR Medical Corp. (TSXV:CVM) (FRANKFURT: B3BN) (OTCQB: CRRVF) (“CVR Medical”) is pleased to announce the signing of an official Letter of Intent with Guangzhou LangRun Equity Investment Management Co., Ltd. (GLR), a professional equity investment fund management platform company headquartered in Guangzhou, China. GLR plans to create the “LangRun Asset Fund” focused on investment in medical devices specific to senior care and healthcare optimization, and which will fund a proposed 35% (CVR) / 65% (GLR) joint venture to market, assemble and distribute CVR’s patented carotid stenotic scan (CSS) device throughout Mainland China.
The Letter of Intent puts CVR in a position to achieve its goal of further expansion into the Asian-Pacific market upon the intended launch of the CSS in 2018. By working in unison with GLR, CVR will enter the Chinese market with the financial resources, stability and guidance necessary to build necessary infrastructure, grow brand awareness and reach a population of nearly 1.5 billion. GLR’s breadth of business experience in the region, mixed with commitment to fund the project in its entirety, will ensure that all operational and clinical requirements are substantiated and every effort is made to achieve approval by the Chinese FDA for market entry.
“We are excited about this proposed equity JV with Guangzhou LangRun to develop the Mainland Chinese market for our CSS medical device, which will leverage the strength of GLR’s strategic partners in government, political, financial and healthcare circles. The agreement we have in place with Guangzhou LangRun will pave the way to one of CVR’s primary goals, entrance into the Chinese market through an equity-based joint venture,” CVR CEO Peter Bakema states. “CVR sees this as a turnkey moment in our evolution into a globally recognized company within the medical device industry. It is a point of great pride for us, and we look forward to working with GLR and its partners to bring our technology to the people of China. This joint venture will act as the framework of future global opportunities for CVR’s patented CSS device. With a significant investment of tens of millions of dollars dedicated to the funding of operational infrastructure, which includes manufacturing, marketing and sales, CVR is effectively able to work with GLR and bring this project to profitability. In addition, the joint venture also calls for the payment of advance royalties and altogether is expected to be dwarfed by the ROI generated by the Joint Venture. CVR is currently negotiating several similar opportunities globally.”
GLR and CVR are working diligently to define the final terms of the Joint Venture Agreement.
For additional information on the organization, leadership and current news, please visit the newly launched company website www.CVRMed.com.

Source


States in the above article that CVR expect to launch the device in 2018 (You are Here) With the size of the market in China alone this CSS medical device is going to have a massive impact, let alone the rest of the world. This is a sleeping lion that is about to roar! Load up on your share whilst the price is still so low. Once approved these prices will never be seen again.....EVER!